Aspirin or P2Y12i monotherapy for secondary prevention in patients with CAD? - PACE-CME

Aspirin or PYi monotherapy for secondary prevention in patients with CAD

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

CODE-EHR, a framework for the use of EHR data in clinical research
CODE-EHR, a framework for the use of EHR data in clinical research
ESC 2022
CODE-EHR, a framework for the use of EHR data in clinical research
- Prof. Folkert Asselbergs, MD, PhD
Is class I recommendation for aspirin use in CVD prevention too strong?
Is class I recommendation for aspirin use in CVD prevention too strong?
ESC 2022
Is class I recommendation for aspirin use in CVD prevention too strong?
- Prof. John Cleland, MD
Understanding the effects of ARNI in acute MI
Understanding the effects of ARNI in acute MI
ESC 2022
Understanding the effects of ARNI in acute MI
- Otavio Berwanger, MD, PhD
Meta-analysis on effects of statins on muscle symptoms
Meta-analysis on effects of statins on muscle symptoms
ESC 2022
Meta-analysis on effects of statins on muscle symptoms
- Prof. Colin Baigent